M Katsogiannou, L Peng… - Current cancer drug …, 2011 - ingentaconnect.com
Castration-resistant prostate cancer remains incurable and a major cause of mortality worldwide. The absence of effective therapeutic approaches for advanced prostate cancer …
M Luna‐Gutiérrez, G Ferro‐Flores… - Journal of Labelled …, 2012 - Wiley Online Library
The conjugation of peptides to gold nanoparticles (AuNPs) produces biocompatible and stable multimeric systems with target‐specific molecular recognition. Peptides based on the …
N Jimenez-Mancilla, G Ferro-Flores… - Current …, 2012 - ingentaconnect.com
The gastrin-releasing peptide receptor (GRP-r) is overexpressed in breast and prostate cancer, and Lys3-bombesin is a peptide that binds with high affinity to the GRP-r. HIV Tat (49 …
N Sadeghzadeh, M Ahmadzadeh, M Erfani - Journal of radioanalytical …, 2013 - Springer
Gastrin-releasing peptide (GRP) receptors are over-expressed in various human tumor including breast and prostate which can be targeted with bombesin for diagnosis and …
PB Pujatti, JM Foster, C Finucane, CD Hudson… - Applied Radiation and …, 2015 - Elsevier
We evaluated and compared a new bombesin analog [Tyr–Gly 5, Nle 14]-BBN (6–14) conjugated to DOTA or DTPA and radiolabeled with In-111 in low and high GRPR …
The aim of the present work was to obtain stabilized high specific activity (HSA) 111In- labeled bombesin conjugates for preclinical evaluations. Parameters influencing the kinetics …
B Jowanaridhi, W Sriwiang - Journal of Physics: Conference …, 2019 - iopscience.iop.org
Bombesin is a 14-amino-acid peptide having the ability to specifically bind gastrin releasing peptide receptors (GRPR) which show over-expression in many types of cancer cells …